CA2606378A1 - Fcrn antibodies and uses thereof - Google Patents

Fcrn antibodies and uses thereof Download PDF

Info

Publication number
CA2606378A1
CA2606378A1 CA002606378A CA2606378A CA2606378A1 CA 2606378 A1 CA2606378 A1 CA 2606378A1 CA 002606378 A CA002606378 A CA 002606378A CA 2606378 A CA2606378 A CA 2606378A CA 2606378 A1 CA2606378 A1 CA 2606378A1
Authority
CA
Canada
Prior art keywords
human
antibody
fcrn
binding portion
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002606378A
Other languages
English (en)
French (fr)
Inventor
Derry Charles Roopenian
Shreeram Akilesh
Gregory James Christianson
Stefka Petkova
Thomas J. Sproule, Jr.
Emanuele Pesavento
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jackson Laboratory
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2606378A1 publication Critical patent/CA2606378A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002606378A 2005-04-29 2006-04-14 Fcrn antibodies and uses thereof Abandoned CA2606378A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67641205P 2005-04-29 2005-04-29
US60/676,412 2005-04-29
PCT/US2006/014182 WO2006118772A2 (en) 2005-04-29 2006-04-14 Fcrn antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CA2606378A1 true CA2606378A1 (en) 2006-11-09

Family

ID=37105335

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002606378A Abandoned CA2606378A1 (en) 2005-04-29 2006-04-14 Fcrn antibodies and uses thereof

Country Status (5)

Country Link
US (1) US20100266530A1 (enExample)
EP (1) EP1879920A2 (enExample)
JP (1) JP2008538919A (enExample)
CA (1) CA2606378A1 (enExample)
WO (1) WO2006118772A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2637929A1 (en) * 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
US20100166734A1 (en) * 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides
US10457719B2 (en) * 2007-09-18 2019-10-29 The Jackson Laboratory Antibodies and FC fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
CA3131470A1 (en) * 2008-04-25 2009-10-29 Takeda Pharmaceutical Company Limited Fc receptor binding proteins
AU2015200004B2 (en) * 2008-04-25 2017-02-16 Bioverativ Therapeutics Inc. Antibodies against fcrn and use thereof
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
WO2010138814A2 (en) * 2009-05-29 2010-12-02 The Brigham And Women's Hospital, Inc. Disrupting fcrn-albumin interactions
MX2012004793A (es) 2009-10-30 2012-07-20 Novozymes Biopharma Dk As Variantes de albumina.
JP5969458B2 (ja) 2010-04-09 2016-08-17 アルブミディクス アクティーゼルスカブ アルブミン誘導体及び変異体
CN103619353B (zh) 2011-06-02 2016-01-06 戴埃克斯有限公司 Fc受体结合蛋白
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
DK2825556T3 (en) 2012-03-16 2018-04-16 Albumedix As albumin Variants
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
KR20150082422A (ko) 2012-11-08 2015-07-15 노보자임스 바이오파마 디케이 에이/에스 알부민 변이체
ZA201506407B (en) * 2013-03-15 2018-11-28 Affibody Ab New polypeptides
CA2902657C (en) * 2013-03-15 2022-05-10 Affibody Ab Fcrn binding polypeptides
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
ES2909014T3 (es) * 2013-11-26 2022-05-04 Brigham & Womens Hospital Inc Composiciones y métodos para modular una respuesta inmunitaria
JP6554473B2 (ja) * 2013-12-24 2019-07-31 アルゲン−エックス ビーブイビーエー ＦｃＲｎアンタゴニスト及び使用方法
EP3134733B1 (en) * 2014-04-25 2020-10-14 The Brigham and Women's Hospital, Inc. Assay and method for treating subjects with immune-mediated diseases
CA2983794A1 (en) * 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
NZ737666A (en) 2014-04-30 2018-10-26 Hanall Biopharma Co Ltd Antibody binding to fcrn for treating autoimmune diseases
US10336825B2 (en) 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
US10323066B2 (en) 2014-09-17 2019-06-18 Affibody Ab Neonatal Fc receptor binding dimer and methods of use
CA3022547A1 (en) * 2015-05-12 2016-11-17 Syntimmune, Inc. Humanized affinity matured anti-fcrn antibodies
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
EP3337816B1 (en) 2015-08-20 2024-02-14 Albumedix Ltd Albumin variants and conjugates
CN106957365B (zh) 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
KR20200096786A (ko) 2017-12-08 2020-08-13 아르제넥스 비브이비에이 전신 중증 근무력증의 치료를 위한 FcRn 길항제의 용도
US12202900B2 (en) 2018-06-08 2025-01-21 argenx BV Compositions and methods for treating immune thrombocytopenia
MX2021004351A (es) 2018-10-16 2021-05-31 UCB Biopharma SRL Metodo para el tratamiento de miastenia grave.
JP7565951B2 (ja) 2019-06-07 2024-10-11 アルジェニクス ビーブイ 皮下投与に好適なＦｃＲｎインヒビターの医薬製剤
CA3163172A1 (en) 2020-01-08 2021-07-15 Peter Verheesen Methods for treating pemphigus disorders
CA3183153A1 (en) * 2020-06-17 2021-12-23 Christian HINDERER Compositions and methods for treatment of gene therapy patients
WO2023016538A1 (en) * 2021-08-13 2023-02-16 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing fcrn and uses thereof
WO2023198806A1 (en) * 2022-04-13 2023-10-19 Ose Immunotherapeutics New class of molecules for selective clearance of antibody
KR20250018382A (ko) 2022-05-30 2025-02-05 한올바이오파마주식회사 안정성이 향상된 항-FcRn 항체 또는 이의 항원 결합 단편
CN119630697A (zh) 2022-06-15 2025-03-14 阿根思有限公司 Ph依赖性hsa结合分子及使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6096871A (en) * 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6992234B2 (en) * 2000-11-06 2006-01-31 The Jackson Laboratory FcRn-based therapeutics for the treatment of auto-immune disorders
JP2007501847A (ja) * 2003-08-08 2007-02-01 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 自己／同種免疫状態の治療用抗ＦｃＲｎ抗体
US7662928B2 (en) * 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions

Also Published As

Publication number Publication date
EP1879920A2 (en) 2008-01-23
WO2006118772A2 (en) 2006-11-09
JP2008538919A (ja) 2008-11-13
WO2006118772A3 (en) 2007-05-31
WO2006118772A9 (en) 2008-03-06
US20100266530A1 (en) 2010-10-21

Similar Documents

Publication Publication Date Title
CA2606378A1 (en) Fcrn antibodies and uses thereof
CN109789201B (zh) 抗人vista抗体及其用途
TWI748984B (zh) Bcma及cd3雙特異性t細胞嚙合抗體構築體
ES2846748T3 (es) Regiones constantes de cadenas pesadas con unión reducida a receptores Fc gamma
ES3040289T3 (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
JP6835586B2 (ja) マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法
EP3838289A1 (en) Anti-tigit antibody and uses thereof
EP3981790A1 (en) Binding molecule specific for cd73 and use of binding molecule
KR20170135860A (ko) 항-pdl1 항체, 활성화 가능한 항-pdl1 항체, 및 이들의 사용 방법
CN106163556A (zh) 基质金属蛋白酶底物和其它可切割部分及其使用方法
JP2018529317A (ja) メソテリン及びｃｄ３に結合する二重特異性抗体構築物
IL253599B2 (en) Substrates cleavable by matrix metalloprotease and serine protease and uses thereof
CA3143995A1 (en) Anti-tigit antibodies
CN108026170A (zh) 抗cd71抗体、可活化抗cd71抗体及其使用方法
US20220235142A1 (en) Anti-ceacam5 monoclonal antibody, preparation method thereof and use thereof
CN107922490A (zh) 抗ITGa3抗体、可活化抗ITGa3抗体及其使用方法
CN106459199A (zh) 抗‑egfrviii抗体及其用途
WO2009086514A1 (en) Humanized monoclonal antibodies and methods of use
CN101720232A (zh) 具有修饰的效应器功能的fc受体结合型多肽
US11597763B2 (en) Anti-Kv1.3 antibodies, and methods of production and use thereof
CA2875451A1 (en) Antibody against transporter and use thereof
US20240390418A1 (en) Anti-variable muc1* antibodies and uses thereof
RU2786434C2 (ru) Антитело к tigit и его использование
AU2024302269A1 (en) T cell engager masking molecules
JP2025533434A (ja) 二重特異性分子安定化組成物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140124